Affordable Access

Access to the full text

Stem Cell Based Therapy Option in COVID-19: Is It Really Promising?

Authors
  • Irmak, Duygu Koyuncu
  • Darıcı, Hakan
  • Karaöz, Erdal
Type
Published Article
Journal
Aging and Disease
Publisher
JKL International LLC
Publication Date
Oct 01, 2020
Volume
11
Issue
5
Pages
1174–1191
Identifiers
DOI: 10.14336/AD.2020.0608
PMID: 33014531
PMCID: PMC7505270
Source
PubMed Central
Keywords
License
Green

Abstract

The COVID-19 patients were first detected in China, in December 2019, then the novel virus with associated pneumonia and other diseases spread quickly to worldwide becoming a serious public health intimidation. Despite all the efforts, the pharmacological agents used for controlling or treating the disease, especially respiratory problems, have not been accomplished so far. Among various treatment options, mesenchymal stem cell-based cellular therapies are being investigated, because of their regeneration ability and multipotency along with other features like immunomodulation, antifibrosis and anti-inflammatory effects. This paper intends to analyze the current clinical trials on stem cell treatment of novel virus, searching and reviewing the available information and the International Clinical Trials Registry Platform (ICTRP) of World Health Organization (WHO). We concluded that the stem cell treatment of COVID-19 is found promising with pilot studies’ results, but still in the early development phase. There is an urgent need for large-scale investigations to confirm and validate the safety and efficacy profile of these therapies with reliable scientific evidence.

Report this publication

Statistics

Seen <100 times